SIRION Biotech, now part of the Revvity portfolio, is a leading European developer and manufacturer of viral vectors for gene and cell therapy applications. Founded in 2005 in Munich, the company specializes in creating advanced viral vector technologies, including adeno-associated virus, lentivirus, and adenovirus platforms. These technologies are crucial for the development of new therapies and vaccines. SIRION Biotech serves a diverse range of clients, including research institutions, pharmaceutical companies, and biotech firms, providing comprehensive viral vector production and customization services. The company operates in the highly specialized market of cell and gene therapy, focusing on both research and preclinical applications. SIRION Biotech's business model revolves around offering tailored solutions for viral vector engineering and manufacturing, thereby facilitating the development of innovative therapies. Revenue is generated through service contracts, licensing agreements, and technology transfer deals. The company is committed to improving clinical outcomes and offers royalty-free access programs to research hospitals to support this mission.

Keywords: viral vectors, gene therapy, cell therapy, adeno-associated virus, lentivirus, adenovirus, biotechnology, clinical applications, research institutions, customization services.